A new antiviral of plant origin一种抗滤过性病原体的植物源
Active substance 有效物质
Panavir is a phytogenic biologically active polysaccharide with molecular weight of 2 megadalton relating to the group of hexose glycoside.
帕拉威尔是一种植物源的生物性有生化活性的多糖
Monosaccharides composition (%):
Xylose - 1.5; 戊醛糖
Rhamnose - 9.0; 鼠李糖,
Glucose - 38.5; 葡萄糖
Galactose - 14.5; 半乳糖
Mannose - 2.5; 甘露糖
Uronic acids - 3.5. 酸
DOSAGE FORM用量构成
Isotonic liquid based solution for infusion is produced in ampoules by 5,0 ml., 2ml.,1 ml in concentration of 0.004%, 0.01% and 0.02% accordingly (0.2 mg active substance). 将等分的药液以浓度0.004%, 0.01% 和0.02%溶解到溶液中，并以5,0 ml., 2ml.,1 ml盛装于玻璃瓶中（含0.2 毫克有效物资），
MECHANISM OF ACTION作用机理
· Panavir is a protector and it defends body's cells from viruses attacks. 帕拉威尔是一种保护剂，它能保护身体细胞不受病毒的攻击，
· The drug is able to inhibit viruses' replication in infected cell cultures and causes significant reduction of titres of infectious virus' activity.
· The drug Panavir enhances viability of infected cells.
本药品能够抑制被感染的细胞中病毒的复制并且显著地减少可感染的活性病毒的浓度。
Pharmacokinetics药物(代谢)动力
After administering Panavir intravenously, polysaccharides are discovered in blood in 5 minutes after injection made and are captured by the cells of reticuloendothelial system of liver and spleen. It is washed out through kidneys, after 20-30 minutes passed polysaccharides are revealed in urine. 在支配静脉内的帕拉威尔后，在注射后的5分钟后，可在血液中发现多糖并且被肝脏和脾内网状内皮组织的细胞俘获并通过肾形矿脉在220-30分钟后排出
，尿液中可显示有多糖。
The trials have shown absence of: 试验表明不会产生以下情况：
Mutagenic, 诱导有机体突变的物质
Teratogenic, 产生畸形的
Cancerogenic, 导致癌的
Allergenic, 引起过敏症
Embryotoxic action胚胎[中]毒作用
PRESCRIPTION TO APPLICATION临床处方
The antiviral Panavir is assigned for treatment of infection contamination caused by DNA and RNA viruses. Chronic recurrent herpes infections (HSV 1, 2, H.Zoster, CMV)
Human papillomavirus infection (HPV)
Viral dermatosis
Mite-borne encephalitis
抗滤过性病原体的帕拉威尔签许用于治疗被DNA和RNA病毒感染的感染体的治疗，慢性的复发性疱疹感染(HSV 1, 2, 带状疹子, CMV)
The ways of application用途
Herpes: 5 ml intravenously (I/V) twice; dosage interval间隔 - 48 hours; reiterate the course of treatment in a month or in exacerbation period. l疱疹：5 ml静脉内注射两次，两次配药时间间隔48小时，依据这样的方式持续治疗一个月或者在病情加重期间按此方法医治。
Papilloma virus infection: 5 ml I/V 5 times; dosage interval: the first 2 injections - 48 hours, the subsequent - one time a week.
Mite-borne encephalitis: 5 ml I/V 3 times; dosage interval - 48 hours.
Administer solution Panavir intravenously slowly by squirts. 帕拉威尔溶液静脉滴注时要给预缓慢进行。
Side effects
The medication is tolerated well; possible complications might be caused by individual intolerance to the drug or heightened sensibility to the constituents of the medication. 本药物耐受性良好，也许会出现因个体对本药物不耐受而引发并发症，也有人对本品出现过敏现象。
The report on clinical study of Panavir efficiency carried out in the Central Scientific Research Institute of Dermatology and Venereology of the Health Ministry of the Russian Federation. 如下是帕拉威尔药效在俄罗斯联盟卫生部所属的中央科学皮肤病和性病研究院得出的临床研究报告
图2病人年龄：（蓝色）20—39岁，（红色）40岁以上；图3病人得病时间：（蓝色）少于一年，（红色）1-5年，（黄色）5-10年；图4 病人复发时间长短：（蓝色）少于7天，（红色）7-10天，（黄色）10天以上；图5：复发率频率：（蓝色）一年3-4次，（红色）6-8次，（黄色）更为严重的
Table 1 表1
ESTIMATION OF THE TREATMENT EFFICIENCY 预计疗效 |
Number of patients病人数量
Recurrence duration复发周期 |
Before treatment治疗前 |
After treatment治疗后 |
17 |
less than 7 days 少于7天 |
5.1 days5.1天 |
31 |
7-10 days 7-10天 |
5.9 days5.9天 |
12 |
11 days and more 11天以上 |
6.8 days6.8天 |
Total: 60 |
|
5.9 days5.9天 | | |
发表于